Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Stock Has Consensus Target Price of $51.40

Posted by Stanley Muller on Oct 4th, 2026

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $51.40.

A number of analysts recently weighed in on COAG shares. HC Wainwright upped their price objective on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Wedbush raised their target price on shares of Hemab Therapeutics from $55.00 to $64.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. Jefferies Financial Group upped their price objective on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, Weiss Ratings lowered Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, September 25th.

Read Our Latest Report on Hemab Therapeutics

Institutional Investors Weigh In On Hemab Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC purchased a new position in Hemab Therapeutics during the 2nd quarter worth $19,226,000. Braidwell LP purchased a new position in Hemab Therapeutics during the 2nd quarter valued at about $5,877,000. State Street Corp purchased a new stake in shares of Hemab Therapeutics in the second quarter valued at $2,825,000. Opaleye Management Inc. purchased a new position in shares of Hemab Therapeutics during the second quarter valued at approximately $1,750,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Hemab Therapeutics during the second quarter worth about $688,000.

Hemab Therapeutics Stock Up 0.2%

Shares of NASDAQ COAG opened at $31.11 on Thursday. The firm’s 50 day simple moving average is $44.44. The company has a market capitalization of $1.45 billion and a P/E ratio of -1.26. Hemab Therapeutics has a fifty-two week low of $23.00 and a fifty-two week high of $55.42.

Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). As a group, research analysts forecast that Hemab Therapeutics will post -3.09 earnings per share for the current year.

Hemab Therapeutics Company Profile

(Get Free Report)

Hemab Therapeutics (NASDAQ: COAG) is a clinical-stage biopharmaceutical company developing treatments for serious and potentially life-threatening bleeding disorders. The company focuses on rare conditions for which existing therapies may be limited, inconvenient, or ineffective for some patients.

Hemab’s lead investigational program, HMB-001, is an engineered bispecific antibody designed to improve blood clotting by enhancing thrombin generation through inhibition of tissue factor pathway inhibitor.